Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axogen, Inc. - Common Stock (NQ: AXGN )

17.45 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13
Open 17.45
Bid (Size) 7.080 (1)
Ask (Size) 23.00 (3)
Prev. Close 17.45
Today's Range 17.45 - 17.45
52wk Range 5.550 - 21.00
Shares Outstanding 41,397,053
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Expectations For Axogen's Future
Via Benzinga
Axogen, Inc. To Host Analyst & Investor Day on March 4th
From Axogen, Inc.
Via GlobeNewswire

Performance

YTD
+6.40%
+6.40%
1 Month
-1.52%
-1.52%
3 Month
+17.43%
+17.43%
6 Month
+31.40%
+31.40%
1 Year
+112.03%
+112.03%

More News

Read More
Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results
From Axogen, Inc.
Via GlobeNewswire
Earnings Scheduled For February 25, 2025
Via Benzinga
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
From Axogen, Inc.
Via GlobeNewswire
Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Axogen, Inc.
Via GlobeNewswire
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Axogen, Inc.
Via GlobeNewswire
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
From Axogen, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
From Axogen, Inc.
Via GlobeNewswire
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
From Axogen, Inc.
Via GlobeNewswire
Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)
From Axogen, Inc.
Via GlobeNewswire
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
From CytoSorbents
Via GlobeNewswire
AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Parker-Hannifin Posts Upbeat Earnings, Joins Under Armour, Zillow Group, YETI Holdings, Eli Lilly And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Axogen, Inc. Announces New Leadership Appointments
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. Reports Second Quarter 2024 Financial Results
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
From Axogen, Inc.
Via GlobeNewswire
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
From Axogen, Inc.
Via GlobeNewswire
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
From Axogen, Inc.
Via GlobeNewswire
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
From Axogen, Inc.
Via GlobeNewswire
AXGN Stock Earnings: Axogen Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.